QuanDx

About:

QuanDx develops life science reagents and molecular diagnostic kits for applications in various diseases.

Twitter/X: quandxinc

Description:

QuanDx Inc. was founded in September 2010 in New York City, NY, USA. In Jan., 2013, QuanDx moved to Bay area of San Francisco, California, the heart of biotech industry. QuanDx’ vision is to develop and commercialize innovative and unique research / clinical diagnostic assays based on proprietary technology for use in clinical and research laboratories worldwide. Our patented technology is based on innovative Yin-Yang Probes which offer multiple benefits in the design and function of molecular based assays. The first commercial product lines will comprise of Q-Fusion leukemia screening kits, AML/ALL leukemia screening kits, BCR-ABL P210/P190 One-tube Quant kits. The ability to detect cancer specific fusion genes is important not only in cancer research, but also increasingly in clinical settings to ensure that correct diagnosis is made and the optimal personalised treatment is chosen. It is the objective of QuanDx to offer a simpler and cost-effective solution for the detection of these important fusion genes.

Total Funding Amount:

$4.25M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Menlo Park, California, United States

Founded Date:

2010-01-01

Contact Email:

info(AT)QuanDx.com

Founders:

Guo Liang Yu, Matthew Lei

Number of Employees:

1-10

Last Funding Date:

2015-12-10

IPO Status:

Private

Industries: